Canaccord lowered the firm’s price target on BioMarin to $91 from $104 and keeps a Hold rating on the shares. The firm updated its model followng the retirement of the company’s CEO as changes in strategy and company directio are still to be determined.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BMRN:
- BioMarin (NASDAQ:BMRN) Gains after Elliott Investment Picks Up Stake
- BioMarin price target lowered to $115 from $125 at Piper Sandler
- BioMarin price target lowered to $111 from $125 at Barclays
- BioMarin names Alexander Hardy CEO, succeeding Jean-Jacques Bienaime
- BioMarin narrows 2023 non-GAAP EPS $1.90-$2.05 from $1.85-$2.10, consensus $1.02